title: The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
abstract: Prostate cancer is the most common solid-organ cancer affecting the male population. Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castrate-resistant state and until recently chemotherapy was the only treatment available with proven survival benefit. Abiraterone is a new class of anti-androgen with proven survival benefit post-chemotherapy. In this review we discuss the characteristics of abiraterone and the clinical trials that led to its approval for the treatment of patients with prostate cancer.
authors.affiliation: Department of Urology, Northampton General Hospital, Northampton, UK. aprawlinson2003@yahoo.co.uk
authors.forename: Alex
authors.initials: A
authors.lastname: Rawlinson
authors.forename: Aza
authors.initials: A
authors.lastname: Mohammed
authors.forename: John
authors.initials: J
authors.lastname: Beatty
authors.forename: Richard
authors.initials: R
authors.lastname: Bell
authors.forename: Marek
authors.initials: M
authors.lastname: Miller
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000736:Androstenes; D000737:Androstenols; D000970:Antineoplastic Agents; C089740:abiraterone